Item 5. Other Information
Item 5. Other Information.
Not applicable.
83
Item 6. Exhibits.
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth below.
Exhibit
Incorporate by
Exhibit
Filed
Number
Description
Form
File No
Date of Filing
No.
Herewith
2.1
Agreement and Plan of Merger, dated June 22, 2023, by and among Aeglea BioTherapeutics, Inc. Aspen Merger Sub I, Inc., Sequoia Merger Sub II, LLC and Spyre Therapeutics, Inc.
8-K
001-37722
06/23/2023
2.1
3.1
Restated Certificate of Incorporation
S-1/A
333-205001
9/14/2015
3.2
3.2
Amended and Restated Bylaws
8-K
001-37722
12/19/2022
3.1
3.3
Certificate of Designation of Series A Non-Voting Convertible Preferred Stock
8-K
001-37722
06/23/2023
3.1
10.1
Securities Purchase Agreement, dated as of June 22, 2023, by and among Aeglea BioTherapeutics, Inc. and each purchaser thereto
8-K
001-37722
06/23/2023
10.1
10.2
Form of Registration Rights Agreement, by and among Aeglea BioTherapeutics, Inc. and each purchaser thereto
8-K
001-37722
06/23/2023
10.2
10.3+
Offer Letter, dated June 22, 2023, by and between Aeglea BioTherapeutics, Inc. and Cameron Turtle
X
10.4#
Antibody Discovery and Option agreement, dated May 25, 2023, by and between Paragon Therapeutics, Inc., Parapyre Holding LLC and Spyre Therapeutics, Inc.
X
10.5+
First Amendment to the Aeglea BioTherapeutics, Inc. 2016 Equity Incentive Plan
X
10.6+
First Amendment to the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan
X
10.7+
Amended and Restated Spyre 2023 Equity Incentive Plan
X
10.8+
Form of Stock Option Agreement under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan
X
10.9#
Asset Purchase Agreement, dated July 27, 2023, by and between Aeglea BioTherapeutics, Inc. and Immedica Pharma AB
X
31.1
Certification of the Principal Executive and Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
X
84
Exhibit
Incorporate by
Exhibit
Filed
Number
Description
Form
File No
Date of Filing
No.
Herewith
32.1(1)
Certification of the Principal Executive and Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
X
101.INS
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
X
101.SCH
Inline XBRL Taxonomy Extension Schema Document
X
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
X
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document
X
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document
X
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
X
104
The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, formatted in Inline XBRL and contained in Exhibit 101
+ Indicates management contract or compensatory plan.
# Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
(1) The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
85
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: August 11, 2023
AEGLEA BIOTHERAPEUTICS, INC.
By:
/s/ Jonathan Alspaugh
Jonathan Alspaugh
President and Chief Financial Officer
(Principal Executive Officer, Principal Financial Officer and duly Authorized Signatory)
86